PERTH, Australia – Australian biotech company Clinical Genomics Pty Ltd., of Sydney, will be able to dramatically expand the U.S. footprint of its liquid biopsy diagnostic to detect recurrent colon cancer following a new pact with the Netherlands-based Qiagen NV for its Paxgene blood collection system.
PERTH, Australia – Australian biotech company Clinical Genomics Pty Ltd., based in Sydney, will be able to dramatically expand the U.S. footprint of its liquid biopsy diagnostic to detect recurrent colon cancer following a new pact with the Netherlands-based Qiagen NV for its Paxgene blood collection system.
PERTH, Australia – A new technology spun out of Singapore's Agency for Science, Technology and Research (A*STAR) could change cancer treatment by building cell-based tumor avatars in the lab to test them against a multitude of drugs.
PERTH, Australia – A new technology spun out of Singapore's Agency for Science, Technology and Research (A*STAR) could change cancer treatment by building cell-based tumor avatars in the lab to test them against a multitude of drugs.
PERTH, Australia – Melbourne-based biotech Starpharma Ltd. expects to file its rolling NDA with the FDA in the next month following positive phase III results for Vivagel BV for preventing recurrent bacterial vaginosis.
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) is asking for industry feedback on whether Australia should change its naming mechanisms for biosimilars and biologics and if it should adopt practices of other international regulators.
PERTH, Australia – Melbourne-based biotech Starpharma Ltd. expects to file its rolling NDA with the FDA in the next month following positive phase III results for Vivagel BV for preventing recurrent bacterial vaginosis.
